Abstract:Abstract In currently ongoing adoptive T-cell therapies, T cells collected from patients are given back to them after ex vivo activation and expansion. In some cases, T cells are transduced with chimeric antigen receptor (CAR) or T-cell receptor (TCR) genes during the ex vivo culture period in order to endow T cells with the desired antigen specificity. Although such strategies are effective in some types of cancer, there remain issues to be solved: (i) the limited number of cells, (ii) it is time-consuming, (iii) it is costly, and (iv) the quality can be unstable. Points (ii) and (iv) can be solved by preparing allogeneic T cells and cryopreserving them in advance and methods are being developed using healthy donor-derived T cells or pluripotent stem cells as materials. Whereas it is difficult to solve (i) and (iii) in the former case, all the issues can be cleared in the latter case. However, in either case, a new problem arises: rejection by the patient’s immune system. Deletion of human leukocyte antigen (HLA) avoids rejection by recipient T cells, but causes rejection by NK cells, which can recognize loss of HLA class I. Various countermeasures have been developed, but no definitive solution is yet available. Therefore, further research and development are necessary.

What problem does this paper attempt to address?

The paper primarily explores the development trends and challenges of adoptive T-cell therapy from autologous cells to allogeneic universal cells. Specifically, the paper attempts to address the following key issues: 1. **Problems with Autologous T-Cell Therapy**: - Limited cell quantity. - Long production time. - High cost. - Unstable product quality. 2. **Advantages and New Challenges of Allogeneic T-Cell Therapy**: - Allogeneic T cells can be pre-prepared and cryopreserved, thus addressing time and quality control issues. - However, allogeneic T cells face immune rejection issues, including T-cell-mediated rejection and natural killer (NK) cell-mediated rejection. 3. **Solutions Using Induced Pluripotent Stem Cells (iPS Cells) to Produce T Cells**: - Using iPS cells can obtain a large number of T cells in mass production. - By selecting iPS cells with specific human leukocyte antigen (HLA) types, immune rejection reactions can be reduced. 4. **New Strategies for Immune Rejection**: - Deleting HLA genes through gene editing technology to avoid T-cell-mediated immune rejection. - Expressing certain inhibitory molecules (such as HLA-E, CD47, etc.) to avoid attacks from NK cells and macrophages. In summary, the paper aims to explore how to overcome various limitations in adoptive T-cell therapy and proposes the use of allogeneic cells and iPS cells as potential solutions.

Trends in cell medicine: from autologous cells to allogeneic universal-use cells for adoptive T-cell therapies